

Robert Schierwagen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3446592/publications.pdf>

Version: 2024-02-01

93
papers

3,492
citations

147566

31
h-index

161609

54
g-index

98
all docs

98
docs citations

98
times ranked

4612
citing authors

#	ARTICLE	IF	CITATIONS
1	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
2	FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. <i>Scientific Reports</i> , 2016, 6, 33453.	1.6	168
3	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
4	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	2.2	134
5	Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. <i>Scientific Reports</i> , 2015, 5, 12931.	1.6	127
6	Circulating microbiome in blood of different circulatory compartments. <i>Gut</i> , 2019, 68, 578-580.	6.1	120
7	Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. <i>Hepatology</i> , 2014, 60, 334-348.	3.6	107
8	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	1.8	97
9	Quantification of Liver Fibrosis at T1 and T2 Mapping with Extracellular Volume Fraction MRI: Preclinical Results. <i>Radiology</i> , 2018, 288, 748-754.	3.6	96
10	Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. <i>Laboratory Investigation</i> , 2012, 92, 1440-1450.	1.7	94
11	Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts. <i>Liver International</i> , 2011, 31, 860-870.	1.9	89
12	HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. <i>Journal of Hepatology</i> , 2012, 57, 1220-1227.	1.8	86
13	Activation of the Mas Receptor by Angiotensin-(1 ⁷) in the Renin-Angiotensin System Mediates Mesenteric Vasodilatation in Cirrhosis. <i>Gastroenterology</i> , 2013, 145, 874-884.e5.	0.6	85
14	Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality. <i>Hepatology</i> , 2018, 67, 1472-1484.	3.6	77
15	Tumor-necrosis factor impairs CD4+ T cell-mediated immunological control in chronic viral infection. <i>Nature Immunology</i> , 2016, 17, 593-603.	7.0	75
16	Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. <i>Nature Communications</i> , 2022, 13, .	5.8	68
17	Statins improve NASH via inhibition of RhoA and Ras. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G724-G733.	1.6	61
18	Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. <i>Gut</i> , 2017, 66, 145-155.	6.1	58

#	ARTICLE	IF	CITATIONS
19	Circulating MicroRNAs as a marker for liver injury in human immunodeficiency virus patients. <i>Hepatology</i> , 2015, 61, 46-55.	3.6	55
20	Rationale for the use of statins in liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, G407-G412.	1.6	52
21	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , 2021, 70, gutjnl-2019-320170.	6.1	47
22	Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure. <i>Liver International</i> , 2020, 40, 1457-1466.	1.9	46
23	Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. <i>Scientific Reports</i> , 2015, 5, 14573.	1.6	45
24	Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis. <i>Hepatology Communications</i> , 2018, 2, 211-222.	2.0	45
25	Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. <i>Gut</i> , 2020, 69, 1535-1536.	6.1	42
26	Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 69.	2.2	40
27	Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats. <i>Frontiers in Physiology</i> , 2013, 4, 195.	1.3	39
28	Extracellular Matrix Remodeling in Chronic Liver Disease. <i>Current Tissue Microenvironment Reports</i> , 2021, 2, 41-52.	1.3	38
29	Combination of CCl ₄ with alcoholic and metabolic injuries mimics human liver fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G182-G194.	1.6	37
30	Managing portal hypertension in patients with liver cirrhosis. <i>F1000Research</i> , 2018, 7, 533.	0.8	36
31	Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis. <i>Frontiers in Physiology</i> , 2015, 6, 359.	1.3	35
32	Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality. <i>Liver International</i> , 2018, 38, 875-884.	1.9	35
33	Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension. <i>Gut</i> , 2015, 64, 1349-1350.	6.1	32
34	Liver Fibrosis in HIV Patients Receiving a Modern cART. <i>Medicine (United States)</i> , 2015, 94, e2127.	0.4	31
35	Fibroblast growth factor 21 is an early predictor of acute-on-chronic liver failure in critically ill patients with cirrhosis. <i>Liver Transplantation</i> , 2018, 24, 595-605.	1.3	31
36	PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension. <i>PLoS ONE</i> , 2014, 9, e108544.	1.1	29

#	ARTICLE	IF	CITATIONS
37	Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis. <i>Medicine (United States)</i> , 2018, 97, e0462.	0.4	29
38	Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0138732.	1.1	29
39	Trust is good, control is better: technical considerations in blood microbiome analysis. <i>Gut</i> , 2020, 69, 1362-1363.	6.1	28
40	Assessment of response to beta-blockers by expression of β 2Arr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. <i>Journal of Hepatology</i> , 2016, 64, 1265-1273.	1.8	27
41	Relaxin reduces susceptibility to post-infarct atrial fibrillation in mice due to anti-fibrotic and anti-inflammatory properties. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 643-649.	1.0	27
42	Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis. <i>Frontiers in Immunology</i> , 2020, 11, 354.	2.2	27
43	Left Ventricular Longitudinal Contractility Predicts Acute to Chronic Liver Failure Development and Mortality After Transjugular Intrahepatic Portosystemic Shunt. <i>Hepatology Communications</i> , 2019, 3, 340-347.	2.0	26
44	Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats. <i>Scientific Reports</i> , 2019, 9, 2256.	1.6	26
45	Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis. <i>Liver International</i> , 2019, 39, 885-893.	1.9	26
46	Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study. <i>Gut</i> , 2018, 67, 593-594.	6.1	25
47	Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers. <i>Aids</i> , 2014, 28, 2081-2090.	1.0	24
48	Activation of the Alternate Renin-Angiotensin System Correlates with the Clinical Status in Human Cirrhosis and Corrects Post Liver Transplantation. <i>Journal of Clinical Medicine</i> , 2019, 8, 419.	1.0	24
49	Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties. <i>International Journal of Cardiology</i> , 2018, 250, 21-28.	0.8	22
50	Dynamic human liver proteome atlas reveals functional insights into disease pathways. <i>Molecular Systems Biology</i> , 2022, 18, e10947.	3.2	22
51	Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2015, 10, e0116768.	1.1	21
52	The Role of miRNA-34a as a Prognostic Biomarker for Cirrhotic Patients with Portal Hypertension Receiving TIPS. <i>PLoS ONE</i> , 2014, 9, e103779.	1.1	20
53	The calcium-activated potassium channel KCa3.1 is an important modulator of hepatic injury. <i>Scientific Reports</i> , 2016, 6, 28770.	1.6	20
54	The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension. <i>Oncotarget</i> , 2018, 9, 36220-36237.	0.8	20

#	ARTICLE	IF	CITATIONS
55	Soluble TIM3 and Its Ligands Galectin-9 and CEACAM1 Are in Disequilibrium During Alcohol-Related Liver Disease and Promote Impairment of Anti-bacterial Immunity. <i>Frontiers in Physiology</i> , 2021, 12, 632502.	1.3	19
56	Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension. <i>PLoS ONE</i> , 2016, 11, e0162144.	1.1	16
57	Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension. <i>Methods in Molecular Biology</i> , 2017, 1627, 91-116.	0.4	16
58	Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients. <i>Liver International</i> , 2019, 39, 1514-1520.	1.9	16
59	Microbiome Patterns in Matched Bile, Duodenal, Pancreatic Tumor Tissue, Drainage, and Stool Samples: Association with Preoperative Stenting and Postoperative Pancreatic Fistula Development. <i>Journal of Clinical Medicine</i> , 2020, 9, 2785.	1.0	16
60	Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3456-3464.	1.1	15
61	Hepatic inflammasome activation as origin of Interleukin-1 β and Interleukin-1 γ in liver cirrhosis. <i>Gut</i> , 2021, 70, 1799-1800.	6.1	14
62	Baseline Presence of NAFLD Predicts Weight Loss after Gastric Bypass Surgery for Morbid Obesity. <i>Journal of Clinical Medicine</i> , 2020, 9, 3430.	1.0	14
63	Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure. <i>JHEP Reports</i> , 2021, 3, 100233.	2.6	14
64	The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 715765.	1.6	14
65	Follistatin-controlled activin-HNF4 α coagulation factor axis in liver progenitor cells determines outcome of acute liver failure. <i>Hepatology</i> , 2022, 75, 322-337.	3.6	14
66	The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. <i>Frontiers in Immunology</i> , 2020, 11, 1352.	2.2	13
67	Quantification of liver fibrosis: extracellular volume fraction using an MRI bolus-only technique in a rat animal model. <i>European Radiology Experimental</i> , 2019, 3, 22.	1.7	12
68	Sex specificity of kidney markers to assess prognosis in cirrhotic patients with TIPS. <i>Liver International</i> , 2020, 40, 186-193.	1.9	12
69	Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis. <i>JHEP Reports</i> , 2021, 3, 100221.	2.6	12
70	Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension. <i>Liver International</i> , 2015, 35, 1393-1402.	1.9	10
71	MicroRNA-155 is upregulated in ascites in patients with spontaneous bacterial peritonitis. <i>Scientific Reports</i> , 2017, 7, 40556.	1.6	10
72	microRNA-200a: A stage-dependent biomarker and predictor of steatosis and liver cell injury in human immunodeficiency virus patients. <i>Hepatology Communications</i> , 2017, 1, 36-45.	2.0	10

#	ARTICLE	IF	CITATIONS
73	TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor. <i>Scientific Reports</i> , 2019, 9, 11598.	1.6	10
74	Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART. <i>PLoS ONE</i> , 2019, 14, e0219526.	1.1	10
75	Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2027.	1.8	10
76	Combination of phosphodiesterase-5 inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. <i>Liver International</i> , 2020, 40, 2228-2241.	1.9	9
77	Hepatic mitochondrial dysfunction in nonalcoholic steatohepatitis: Readout or reason?. <i>Hepatology</i> , 2016, 63, 1729-1732.	3.6	8
78	Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?. <i>Journal of Hepatology</i> , 2020, 73, 980-982.	1.8	8
79	Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease. <i>Liver Transplantation</i> , 2020, 26, 1652-1657.	1.3	8
80	β -Arrestin2 is increased in liver fibrosis in humans and rodents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 27082-27084.	3.3	8
81	Targeting the cytoplasmic polyadenylation element-binding protein CPEB4 protects against diet-induced obesity and microbiome dysbiosis. <i>Molecular Metabolism</i> , 2021, 54, 101388.	3.0	8
82	Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis. <i>PLoS ONE</i> , 2019, 14, e0222840.	1.1	7
83	Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3308.	1.8	7
84	"Tipping" extracellular matrix remodeling towards regression of liver fibrosis: novel concepts. <i>Minerva Gastroenterology</i> , 2017, 64, 51-61.	0.3	6
85	Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis. <i>PLoS ONE</i> , 2020, 15, e0231701.	1.1	4
86	Novel Targets and Drug Development in Portal Hypertension. <i>Current Hepatology Reports</i> , 2019, 18, 187-196.	0.4	3
87	Regulation of uridine diphosphate-glucuronosyltransferase-1A expression by miRNA-214-5p and miRNA-486-3p. <i>Epigenomics</i> , 2021, 13, 271-283.	1.0	3
88	Role of circulating angiogenin levels in portal hypertension and TIPS. <i>PLoS ONE</i> , 2021, 16, e0256473.	1.1	2
89	A New Treatment for Chronic Hepatitis B and D Offers Novel Insights Into Obesity and Hepatic Steatosis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 649-651.	2.3	1
90	Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis. <i>Current Hepatology Reports</i> , 2016, 15, 271-279.	0.4	0

#	ARTICLE	IF	CITATIONS
91	Animal Models When Examining the Gut-Liver Axis. , 2019, , 235-264.		0
92	Cohort study evaluating predictors of therapeutic success after sleeve gastrectomy or Roux-en-Y gastric bypass. Annals of Laparoscopic and Endoscopic Surgery, 0, 7, 1-1.	0.5	0
93	Effects of Ethanol Feeding in Early-Stage NAFLD Mice Induced by Western Diet. Livers, 2021, 1, 27-39.	0.8	0